Investor Presentation

**Financial Highlights:** Orchid Pharma reported a 12% increase in sales for Q2 FY 2024-25, reaching ₹222.7 Cr, up from ₹198.8 Cr in Q2 FY 2023-24. For the first half, sales increased by 22%, totaling ₹467.1 Cr compared to ₹381.7 Cr in the previous year.

EBITDA improved by 20% to ₹37.5 Cr, with a corresponding margin of 17%. The company also saw a strong growth in EBITDA for the first half, rising 44% year-over-year to ₹78.6 Cr. **Strategic Initiatives and Growth Drivers:** Orchid Pharma continues to focus on enhancing operational efficiency and expanding its market presence.

The positive growth in sales and EBITDA indicates effective cost management and strategic execution. **Business Developments:** The ongoing initiatives to streamline operations and improve product offerings are expected to drive future growth. **Market Position and Competitive Advantage:** The company maintains a competitive edge due to improved gross margins and sales growth, positioning it favorably in the pharmaceutical market. **Investor Implications:** The robust sales and profitability growth suggest a positive outlook for Orchid Pharma, potentially offering attractive opportunities for investors as the company capitalizes on its strategic initiatives.